On September 25, 2018 Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, reported that management will participate at both the upcoming KBC Healthcare Conference and the Leerink Partners Roundtable Series: Rare Disease & Oncology (Press release, Celyad, SEP 25, 2018, View Source [SID1234532510]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The KBC Healthcare Conference will take place in New York, NY on September 27, 2018.

The Leerink Partners Roundtable Series: Rare Disease & Oncology will take place in New York, NY on October 2-3, 2018 and the Company is scheduled to present on Wednesday, October 3 at 4:00 p.m. ET. A live webcast of the presentation can be accessed at View Source An archived webcast recording will also be available under Events & Webcasts in the Investors section of the Company’s website.